Search

Search Constraints

You searched for: Author/Creator Subbiah, V.

Search Results

1. 1871 Inhibition of mTOR in combination with chemotherapy and angiogenic blockade shows activity in metaplastic breast cancer, an aggressive, chemo-refractory subtype of triple-negative breast cancer (TNBC). (September 2015)

2. 3007 Comprehensive genomic profiling characterizes the cpectrum of non-V600E activating BRAF alterations Including BRAF fusions in lung cancer. (September 2015)

4. DNA Damage Response (DDR) Basket of Baskets (D-BOB) Trial: Phase 1/2 Study of the ATR inhibitor (ATRi) berzosertib and PD-L1 inhibitor avelumab in patients (pts) with advanced solid tumors with DDR molecular alterations. (October 2022)

5. Identifying FGFR2 fusions/rearrangements in cholangiocarcinoma patients using a novel cfDNA algorithm for treatment with RLY-4008, a highly selective irreversible FGFR2 inhibitor. (October 2022)

6. NCI10329: Phase Ib Sequential Trial of Agents against DNA Repair (STAR) Study to investigate the sequential combination of the Poly (ADP-Ribose) Polymerase inhibitor (PARPi) olaparib (ola) and WEE1 inhibitor (WEE1i) adavosertib (ada) in patients (pts) with DNA Damage Response (DDR)-aberrant advanced tumors, enriched for BRCA1/2 mutated and CCNE1 amplified cancers. (October 2022)

10. Drug development in the MD Anderson Cancer Center (MDACC) Clinical Translational Research Center (CTRC) – 2011–2015: The challenge of precision medicine in a very broad playing field. (December 2016)